{
  "id": 3653184,
  "title": "Mpm Bioventures sells $461,545 in Entrada Therapeutics stock",
  "url": "https://urgent.news/2026/08/27/mpm-bioventures-sells-461-545-in-entrada-therapeutics-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-27T03:16:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/mpm-bioventures-sells-461545-in-entrada-therapeutics-stock-93CH-4878295"
  },
  "original_language": "en",
  "account": null,
  "summary": "MPM BioVentures 2014, L.P., a 10% owner and director of Entrada Therapeutics, Inc. (NASDAQ:TRDA), sold $461,545 worth of the company's stock over three days in late August 2026. The stock, which trades at $7, has seen a nearly 8% decline over the past week, nearing its 52-week low of $5.02. The sales, comprising 62,614 shares sold at weighted average prices ranging from $7.06 to $7.54 per share, reduced the indirect beneficial ownership to 4,318,348 shares. Despite the financial headwinds and a consensus Buy rating with price targets ranging from $11 to $25, the biotech company continues to advance in its research efforts, including receiving clearance to escalate the dose in its ongoing ELEVATE-45-201 study for Duchenne muscular dystrophy.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock",
        "url": "https://urgent.news/2026/08/27/mpm-bioventures-2018-sells-461-545-of-entrada-therapeutics-stock",
        "published": "2026-08-27T03:16:31.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}